eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2004
vol. 8
 
Share:
Share:
abstract:

Effects of interferonotherapy and Lamivudine monotherapy of HBV infection in a patient with chronic myelogenous leukemia. Case report

Bożena Karczmarek-Borowska
,
Hanna Fota-Markowska
,
Joanna Lis-Tonder
,
Roma Modrzewska

Współcz Onkol (2004) vol. 8; 1 (38–41)
Online publish date: 2004/02/20
View full text Get citation
 
HBV infection brings about some serious prognostic and therapeutic problems especially in the case of complicated hematopoietic, lymphatic and reticuloendothelial system malignancies. In this paper, the effect of interferonotherapy and Lamivudine monotherapy of HBV infection of a patient with chronic myelogenous leukemia (CML) is presented. The 30-year-old patient with coexisting HBV infection, chronic hepatitis B and chronic myelogenous leukemia (CML Ph), treated with chemotherapy, then unsuccessful bone marrow transplantations was assigned to INF-therapy (doses of 2-5 mln three times a week, based on serological HBV markers profile: HBsAg(+), HBeAg(+), anti-HBc IgM(+) and viremia 6418 pg/ml (Digene Hybrid Capture System - Murex). Viremia decreased to 3 808 pg/ml after 4 months and to 2 907 pg/ml after 7 months of therapy, whereas HBsAg, HBeAg and anti-HBcIgM were present. After 11 months of therapy serologic HBV markers were still present, but the HBV-DNA serum level increased to 6 209 pg/ml. In view of these data, a decision of Lamivudine administration with a daily dose of 150 mg was made. After three months of this therapy, an undetectable serum HBV-DNA level and a normal serum transaminase activity without serum HBsAg clearance were found. Then, with the antiviral therapy with the same dose of Lamivudine continued, BMT procedure was performed. The presented case report confirms the role of active immunization of patients with hematopoietic system disorders.
keywords:

HBV infection, IFN, Lamivudine, chronic myelogenous leukemia

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.